Cellyan Biotechnology Co., Ltd (HKPD)

Cellyan Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023
Cash & Equivalents	0.75	0.62	0.52
Trading Asset Securities	2.26	-	-
Cash & Short-Term Investments	3.01	0.62	0.52
Cash Growth	385.10%	18.10%	-
Accounts Receivable	4.66	3.7	1.7
Other Receivables	0.06	0.02	0.03
Receivables	4.71	3.72	1.73
Inventory	0.56	0.93	0.19
Prepaid Expenses	0.16	0.09	0.07
Restricted Cash	0	0.01	-
Other Current Assets	0.28	2.44	0.24
Total Current Assets	8.73	7.8	2.75
Property, Plant & Equipment	0.59	0.83	0.65
Other Intangible Assets	0.1	0.03	0
Total Assets	9.42	8.67	3.41
Accounts Payable	1.73	1.82	1.68
Accrued Expenses	0.09	0.09	0.15
Short-Term Debt	-	0.03	-
Current Portion of Long-Term Debt	0.37	0.18	0.06
Current Portion of Leases	0.49	0.63	0.36
Current Income Taxes Payable	0.11	0.22	0.02
Current Unearned Revenue	0.12	0.19	0.27
Other Current Liabilities	0	0	0.01
Total Current Liabilities	2.92	3.18	2.55
Long-Term Debt	1.5	1.12	0.12
Long-Term Leases	0.01	0.12	0.15
Total Liabilities	4.43	4.41	2.82
Common Stock	0.01	0.01	0.01
Additional Paid-In Capital	3.46	3.02	0.39
Retained Earnings	1.5	1.53	0.2
Comprehensive Income & Other	0.01	-0.3	-0.01
Shareholders' Equity	4.99	4.25	0.59
Total Liabilities & Equity	9.42	8.67	3.41
Total Debt	2.37	2.09	0.69
Net Cash (Debt)	0.63	-1.47	-0.17
Net Cash Per Share	0.06	-0.20	-0.02
Filing Date Shares Outstanding	11	10	6.84
Total Common Shares Outstanding	11	10	6.84
Working Capital	5.81	4.63	0.2
Book Value Per Share	0.45	0.43	0.09
Tangible Book Value	4.89	4.22	0.58
Tangible Book Value Per Share	0.44	0.42	0.08
Machinery	0.19	0.14	0.18
Leasehold Improvements	0.07	0.05	0.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q